The IDH paradox: Meta-analysis of alkylating chemotherapy in IDH-wild type and -mutant lower grade gliomas Article

Kinslow, Connor J, Roy, Soumyajit, Iwamoto, Fabio M et al. (2024). The IDH paradox: Meta-analysis of alkylating chemotherapy in IDH-wild type and -mutant lower grade gliomas . NEURO-ONCOLOGY, 26(10), 1839-1849. 10.1093/neuonc/noae102

cited authors

  • Kinslow, Connor J; Roy, Soumyajit; Iwamoto, Fabio M; Brown, Paul D; Destephano, David M; Canoll, Peter D; Qureshi, Summer S; Gallito, Matthew; Sisti, Michael B; Bruce, Jeffrey N; Horowitz, David P; Kachnic, Lisa A; Neugut, Alfred; Yu, James B; Mehta, Minesh P; Cheng, Simon K; Wang, Tony JC

sustainable development goals

authors

publication date

  • June 29, 2024

published in

keywords

  • ADJUVANT TEMOZOLOMIDE
  • CENTRAL-NERVOUS-SYSTEM
  • Clinical Neurology
  • DIFFUSE GLIOMAS
  • Life Sciences & Biomedicine
  • Neurosciences & Neurology
  • OLIGODENDROGLIOMA
  • OPEN-LABEL
  • Oncology
  • PHASE-III TRIAL
  • PROCARBAZINE
  • RADIOTHERAPY
  • Science & Technology
  • TEMOZOLOMIDE CHEMOTHERAPY
  • VINCRISTINE
  • alkylating chemotherapy
  • glioma
  • isocitrate-dehydrogenase
  • meta-analysis
  • radiotherapy

Digital Object Identifier (DOI)

publisher

  • OXFORD UNIV PRESS INC

start page

  • 1839

end page

  • 1849

volume

  • 26

issue

  • 10